Skip to content

Study · Systematic review · 2026

14 results

Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Kamrul-Hasan ABM, Chatterjee S, Ashraf H, Nagendra L, Khalil I, Hasan M, Ahsan A, Dutta D

Diabetes, obesity & metabolism6 Jul 2026Cited by 2 (Europe PMC)

PMID42410325 (opens in a new tab)PMCIDPMC13538747 (opens in a new tab)DOI10.1111/dom.71058 (opens in a new tab)PepBankPUB-42410325
Source linkPubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity without diabetes, mazdutide 3 mg reduced body weight more than placebo (mean difference -6.56%, very low certainty).

    In plain wordsIn adults with overweight or obesity without diabetes, mazdutide 3 mg lowered body weight more than placebo, but the evidence is very uncertain.

    Peptide
    Mazdutide
    Outcome
    DecreasePercent body weight change, overweight/obesity without diabetes (3 mg)
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mgAs given in this study (human).

    Measurements

    Mean difference in body weight
    −6.56%
    mazdutide 3 mg vs placebo

    Source sentences

    Summary
    In overweight/obesity without diabetes, mazdutide 3, 4, and 6 mg reduced body weight more than placebo (MDs -6.56%, -9.92%, and -11.1%, respectively; very low COE due to substantial heterogeneity and few trials).
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity without diabetes, mazdutide 4 mg reduced body weight more than placebo (mean difference -9.92%, very low certainty).

    In plain wordsIn adults with overweight or obesity without diabetes, mazdutide 4 mg lowered body weight more than placebo, but the evidence is very uncertain.

    Peptide
    Mazdutide
    Outcome
    DecreasePercent body weight change, overweight/obesity without diabetes (4 mg)
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4 mgAs given in this study (human).

    Measurements

    Mean difference in body weight
    −9.92%
    mazdutide 4 mg vs placebo

    Source sentences

    Summary
    In overweight/obesity without diabetes, mazdutide 3, 4, and 6 mg reduced body weight more than placebo (MDs -6.56%, -9.92%, and -11.1%, respectively; very low COE due to substantial heterogeneity and few trials).
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity without diabetes, mazdutide 6 mg reduced body weight more than placebo (mean difference -11.1%, very low certainty).

    In plain wordsIn adults with overweight or obesity without diabetes, mazdutide 6 mg lowered body weight more than placebo, but the evidence is very uncertain.

    Peptide
    Mazdutide
    Outcome
    DecreasePercent body weight change, overweight/obesity without diabetes (6 mg)
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    6 mgAs given in this study (human).

    Measurements

    Mean difference in body weight
    −11.1%
    mazdutide 6 mg vs placebo

    Source sentences

    Summary
    In overweight/obesity without diabetes, mazdutide 3, 4, and 6 mg reduced body weight more than placebo (MDs -6.56%, -9.92%, and -11.1%, respectively; very low COE due to substantial heterogeneity and few trials).
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, mazdutide 4 and 6 mg reduced body weight versus placebo (moderate certainty).

    In plain wordsIn adults with type 2 diabetes, mazdutide 4 and 6 mg lowered body weight more than placebo.

    Peptide
    Mazdutide
    Outcome
    DecreaseBody weight change in type 2 diabetes versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4 mg and 6 mgAs given in this study (human).

    Source sentences

    Summary
    In T2D, mazdutide 4 and 6 mg reduced body weight and HbA1c versus placebo (moderate COE) and also outperformed dulaglutide for both outcomes.
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, mazdutide 4 and 6 mg reduced HbA1c versus placebo (moderate certainty).

    In plain wordsIn adults with type 2 diabetes, mazdutide 4 and 6 mg lowered HbA1c more than placebo.

    Peptide
    Mazdutide
    Outcome
    DecreaseHbA1c change in type 2 diabetes versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    4 mg and 6 mgAs given in this study (human).

    Source sentences

    Summary
    In T2D, mazdutide 4 and 6 mg reduced body weight and HbA1c versus placebo (moderate COE) and also outperformed dulaglutide for both outcomes.
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, mazdutide 4 and 6 mg outperformed dulaglutide for body weight reduction.

    In plain wordsIn adults with type 2 diabetes, mazdutide 4 and 6 mg lowered body weight more than dulaglutide.

    Peptide
    Mazdutide
    Outcome
    DecreaseBody weight change in type 2 diabetes versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4 mg and 6 mgAs given in this study (human).

    Source sentences

    Summary
    In T2D, mazdutide 4 and 6 mg reduced body weight and HbA1c versus placebo (moderate COE) and also outperformed dulaglutide for both outcomes.
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  7. 07HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, mazdutide 4 and 6 mg outperformed dulaglutide for HbA1c reduction.

    In plain wordsIn adults with type 2 diabetes, mazdutide 4 and 6 mg lowered HbA1c more than dulaglutide.

    Peptide
    Mazdutide
    Outcome
    DecreaseHbA1c change in type 2 diabetes versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    4 mg and 6 mgAs given in this study (human).

    Source sentences

    Summary
    In T2D, mazdutide 4 and 6 mg reduced body weight and HbA1c versus placebo (moderate COE) and also outperformed dulaglutide for both outcomes.
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  8. 08HumanSystematic reviewEfficacy outcome

    In pooled trials in adults with overweight, obesity or type 2 diabetes, mazdutide improved waist circumference.

    In plain wordsIn pooled trials, mazdutide improved waist size in adults with overweight, obesity or type 2 diabetes, compared with the comparison treatments.

    Peptide
    Mazdutide
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mazdutide also improved waist circumference, lipids, liver enzymes, and uric acid levels.
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  9. 09HumanSystematic reviewEfficacy outcome

    In pooled trials in adults with overweight, obesity or type 2 diabetes, mazdutide improved lipids.

    In plain wordsIn pooled trials, mazdutide improved blood fat levels in adults with overweight, obesity or type 2 diabetes, compared with the comparison treatments.

    Peptide
    Mazdutide
    Outcome
    Direction not reportedLipids
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Analysis
    Secondary
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mazdutide also improved waist circumference, lipids, liver enzymes, and uric acid levels.
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  10. 10HumanSystematic reviewEfficacy outcome

    In pooled trials in adults with overweight, obesity or type 2 diabetes, mazdutide improved liver enzymes.

    In plain wordsIn pooled trials, mazdutide improved liver enzyme levels in adults with overweight, obesity or type 2 diabetes, compared with the comparison treatments.

    Peptide
    Mazdutide
    Outcome
    DecreaseLiver enzymes
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mazdutide also improved waist circumference, lipids, liver enzymes, and uric acid levels.
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  11. 11HumanSystematic reviewEfficacy outcome

    In pooled trials in adults with overweight, obesity or type 2 diabetes, mazdutide improved uric acid levels.

    In plain wordsIn pooled trials, mazdutide improved uric acid levels in adults with overweight, obesity or type 2 diabetes, compared with the comparison treatments.

    Peptide
    Mazdutide
    Outcome
    DecreaseUric acid
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Analysis
    Secondary
    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mazdutide also improved waist circumference, lipids, liver enzymes, and uric acid levels.
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  12. 12HumanSystematic reviewSafety outcome

    In pooled trials, gastrointestinal adverse events were more frequent with mazdutide than with comparators.

    In plain wordsIn pooled trials, stomach and gut side effects were more common with mazdutide than with the comparison treatments.

    Peptide
    Mazdutide
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Analysis
    Secondary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Gastrointestinal adverse events were more frequent
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  13. 13HumanSystematic reviewSafety outcome

    In pooled trials, serious adverse events with mazdutide were comparable with those of the comparators.

    In plain wordsIn pooled trials, mazdutide caused about as many serious side effects as the comparison treatments.

    Peptide
    Mazdutide
    Outcome
    No significant changeSerious adverse events
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Gastrointestinal adverse events were more frequent, but serious adverse events and treatment discontinuation rates were comparable with those of the comparators.
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.
  14. 14HumanSystematic reviewSafety outcome

    In pooled trials, treatment discontinuation rates with mazdutide were comparable with those of the comparators.

    In plain wordsIn pooled trials, about as many people stopped mazdutide as stopped the comparison treatments.

    Peptide
    Mazdutide
    Outcome
    No significant changeTreatment discontinuation
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Gastrointestinal adverse events were more frequent, but serious adverse events and treatment discontinuation rates were comparable with those of the comparators.
    2 context sentences
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, and ClinicalTrials.gov to 20 February 2026.
    Summary · context
    Nine RCTs (N = 2292; most with low risk of bias) were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.